Press coverage about AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) has trended somewhat positive this week, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. AEterna Zentaris earned a daily sentiment score of 0.23 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 44.9767018620182 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of AEterna Zentaris (NASDAQ:AEZS) remained flat at $$2.25 on Thursday. 180,500 shares of the company’s stock traded hands, compared to its average volume of 263,429. The stock has a market capitalization of $35.70, a PE ratio of -1.24 and a beta of 0.87. AEterna Zentaris has a one year low of $0.78 and a one year high of $3.75.
AEZS has been the topic of several research reports. HC Wainwright set a $3.00 price objective on shares of AEterna Zentaris and gave the stock a “buy” rating in a research note on Wednesday, November 29th. Maxim Group set a $4.00 price objective on shares of AEterna Zentaris and gave the stock a “buy” rating in a research note on Thursday, December 21st.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.